...Celsus completed its merger with Volution, with the newco to be named Akari Therapeutics plc (NASDAQ:AKTX...
...newco to be named Akari Therapeutics plc (NASDAQ:AKTX, New York, N.Y.) (see BioCentury, Aug. 24). Volution Immuno Pharmaceuticals S.A....

...contingent upon Celsus obtaining shareholder approval of the financing and the company’s planned acquisition of Volution Immuno Pharmaceuticals S.A....

...dosing advantage over Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN). Coversin is owned by Geneva-based Volution Immuno Pharmaceuticals S.A....
...backers for Volution were about five people who put about $20 million into the company. Volution...

...Volution in a stock transaction, with the newco to be named Akari Therapeutics. Celsus and Volution...
...quarter and GBS and aHUS in 2016. The deal is expected to close this quarter. Volution Immuno Pharmaceuticals S.A....

...Celsus Therapeutics plc (NASDAQ:CLTX) said that after it reverse-merges with Volution Immuno Pharmaceuticals S.A. (Geneva, Switzerland) it will raise...
...which the combined company will be named Akari Therapeutics plc (NASDAQ:AKTX). The lead product is Volution's...

...mg Pradaxa twice daily vs. warfarin in about 724 patients. RE-CIRCUIT is part of Boehringer’s RE-VOLUTION...

...is conducting the trial with Harvard Clinical Research Institute. RE-DUAL PCI is part of Boehringer’s RE-VOLUTION...